(A) number of incidence cases by 2035; (B) projected ASR for incidence from 2035; (C) number of prevalence cases by 2035; (D) projected ASR for prevalence by 2035; (E)number of cas... by Junjie Chen (48472)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

DALYs rate and SDI across all regions between1990 and 2021 (a). DALYs rate across all countries in 2021 by SDI (b). DALYs disability-adjusted life years, SDI socio-demographic inde... by Juanjuan Li (399633)

Preparatory neuronal activity in ALM is decreased, but remains significant in quiet trials devoid of movements. by Vahid Esmaeili (12700352)

Prevalence, death and DALY rate per 100,000 (age-standardized) for both sexes. by Negar Omidi (10352282)

Subjects:

The number of expected vaccinations decreases with the expected vaccination time, whereas the peak of infections increases. by Simon K. Schnyder (16632244)

Costs and Benefits of Popular <i>P</i>‑Value Correction Methods in Three Models of Quantitative Omic Experiments by Steven R. Shuken (14500192)

“…We show how increasing sample size, decreasing variability, or increasing effect size can enable the detection of all true changes while still correcting <i>p</i>-values, and we present basic guidelines for omic experimental design. …”

Data Sheet 1_Global burden and trends of occupational noise-induced hearing loss (1990–2021) and projection to 2040.pdf by Xin Gong (592328)

“…</p>Results<p>In 2021, the global burden of ONIHL remained substantial, with a total of 7,847,444.59 DALYs (95% uncertainty intervals [UI]: 5,313,648.10–10,980,789.34), indicating a 104.46% increase compared with that in 1990. …”

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Amino acids eigenvector centrality values mapped on the protein structure of the following Spike variants: a) Omicron₁; b) Wild Type; c) Delta. by Ugo Lomoio (16624608)

“…The decrease of eigenvector centrality of RBD domain of the Omicron₁ variants is shown by the presence of a larger number of blue colored nodes.…”

Species occurrence along the NO₃¯ gradient (sorted by decreasing 25th percentile values). by Willem Kaijser (12872371)

Influence of the posterior cross vein (PCV) position on <i>A</i>_S / <i>A</i>_C. by Kazuki Sugiyama (1433809)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Sensitivity analysis for cost per disability-adjusted life-year (DALY) averted. by Maitreyi Sahu (8691129)

Subjects:

Mean values of “I feel bored” item. by Ezel Üsten (16548547)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Refinement of scrambles, with no USM decreases. by Jedediah M. Singer (10331212)

Determination of p-values by permutation tests. by Sarah A. Johnson (11355817)